Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 197
- Registration Number
- NCT01375478
Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction
- First Posted Date
- 2011-06-15
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 168
- Registration Number
- NCT01374321
- Locations
- 🇩🇰
Aarhus University Hospital, Aalborg, Denmark
🇩🇰Odense University Hospital, Odense, Denmark
🇫🇷Hôpital La Timone, Marseille, France
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations
Phase 2
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2016-02-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT01372384
A Study of RO5428029 in Healthy Volunteers and Patients With Chronic Hepatitis C
Phase 1
Completed
- Conditions
- Hepatitis C, Chronic, Healthy Volunteer
- Interventions
- Drug: RO5428029Drug: placebo
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 42
- Registration Number
- NCT01371162
A Pharmacokinetic Study of RO4917523 in Healthy Japanese and Caucasian Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: RO4917523Drug: placebo
- First Posted Date
- 2011-06-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 42
- Registration Number
- NCT01368926
A Study of RO4995819 in Combination With Citalopram in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT01367756
STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1232
- Registration Number
- NCT01367665
- Locations
- 🇦🇺
Premier Specialists, Kogarah, New South Wales, Australia
🇦🇷Inst. de Oncologia Angel H. Roffo ; Servicio de Oncologia, Buenos Aires, Argentina
🇦🇺Skin and Cancer Foundation Australia, Westmead, New South Wales, Australia
A Study on The Effect of Multiple Dose Carbamazepine on Single Dose Pharmacokinetics of RO4917838 in Healthy Volunteers
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT01365403
A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT01363999
A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3
- Registration Number
- NCT01363986
© Copyright 2025. All Rights Reserved by MedPath